MedTrace Logo

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients

NCT02482077 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2018-03-19

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability, and efficacy of Sofosbuvir containing regimens in treatment-naive or treatment-experienced patients with HCV genotypes 2 infection.

Conditions

  • Chronic Hepatitis C Infection

Interventions

DRUG

SOF+RBV

Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).

DRUG

SOF+DCV

Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60mg tablet administered once daily.

DRUG

LDV/SOF

Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily

Sponsors & Collaborators

  • Beijing 302 Hospital

    collaborator OTHER

  • Humanity and Health Research Centre

    lead OTHER

Principal Investigators

  • George KK Lau, MD · Humanity and Health GI and Liver Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-12-31
Completion
2018-03-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02482077 on ClinicalTrials.gov